Status:
UNKNOWN
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Lead Sponsor:
Hallym University Medical Center
Conditions:
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Eligibility:
All Genders
19+ years
Brief Summary
Real World Data (RWD) obtained from real clinical sites is data obtained after administering a drug to patients with different characteristics in daily practice, and Real World Evidence (RWE) is estab...
Detailed Description
Most drugs are introduced into the medical market based on efficacy derived from randomized controlled trials (RCTs) in a subset of patient groups in which the age, presence of comorbidities, and gene...
Eligibility Criteria
Inclusion
- Prospective population
- Patients aged 19 years or older and histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
- Patients with locally advanced or metastatic disease for which curative resection is not possible.
- Patients who have failed fluoropyrimidine and platinum (cisplatin or oxaliplatin)-based chemotherapy as palliative first-line therapy
- Patients who is starting ramucirumab/paclitaxel combination therapy after the study initiation date
Exclusion
- Patients receiving ramucirumab monotherapy
- Patients receiving ramucirumab/paclitaxel in clinical trial or receiving without being covered by health insurance
- Patients unable to communicate or incapable of understanding documents for patient report outcomes
- Historical retrospective population
- Inclusion Criteria:
- Patients aged 19 years or older and histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
- Patients with locally advanced or metastatic disease for which curative resection is not possible
- Patients who have failed platinum-based palliative first-line therapy, and who started the following second-line therapy: taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy, before May 1, 2018
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT04915807
Start Date
June 1 2021
End Date
September 1 2023
Last Update
June 7 2021
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Hallym University Sacred Heart Hospital
Anyang, South Korea, 14068
2
Kyungpook National University Chilgok Hospital
Daegu, South Korea, 41404
3
Keimyung University Dongsan Medical Center
Daegu, South Korea, 42601
4
Seoul National University Bundang Hospital
Seongnam, South Korea, 13620